MEP10608A - Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity - Google Patents

Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity

Info

Publication number
MEP10608A
MEP10608A MEP-106/08A MEP10608A MEP10608A ME P10608 A MEP10608 A ME P10608A ME P10608 A MEP10608 A ME P10608A ME P10608 A MEP10608 A ME P10608A
Authority
ME
Montenegro
Prior art keywords
dyslipidemia
obesity
prevention
treatment
pyrazole derivative
Prior art date
Application number
MEP-106/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Michele Arnone
Mohammed Bensaid
Jean-Marc Herbert
Hassan Massoud Heshmati
Philip Janiak
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34426973&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP10608(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR0312553A external-priority patent/FR2861300B1/fr
Priority claimed from FR0314763A external-priority patent/FR2861301B1/fr
Priority claimed from FR0401193A external-priority patent/FR2861302A1/fr
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MEP10608A publication Critical patent/MEP10608A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MEP-106/08A 2003-10-24 2004-10-22 Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity MEP10608A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR0312553A FR2861300B1 (fr) 2003-10-24 2003-10-24 Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
FR0314763A FR2861301B1 (fr) 2003-10-24 2003-12-15 Utilisation du derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique.
FR0401193A FR2861302A1 (fr) 2003-10-24 2004-02-05 Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique.
FR0403252A FR2861303A1 (fr) 2003-10-24 2004-03-26 Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
PCT/FR2004/002715 WO2005046689A2 (fr) 2003-10-24 2004-10-22 Utilisation d’un derive du pyrazole pour la prevention et le traitement des dyslipidemies et des maladies associees aux dyslipidemies et/ou a l’obesite

Publications (1)

Publication Number Publication Date
MEP10608A true MEP10608A (en) 2010-06-10

Family

ID=34426973

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-106/08A MEP10608A (en) 2003-10-24 2004-10-22 Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity

Country Status (18)

Country Link
US (2) US20070072907A1 (fr)
EP (1) EP1680117A2 (fr)
JP (1) JP2007509113A (fr)
KR (1) KR20060100443A (fr)
AR (3) AR047764A1 (fr)
AU (1) AU2004289078A1 (fr)
BR (1) BRPI0415538A (fr)
CA (1) CA2543582A1 (fr)
FR (1) FR2861303A1 (fr)
IL (1) IL175103A0 (fr)
MA (1) MA28105A1 (fr)
ME (1) MEP10608A (fr)
NZ (1) NZ547375A (fr)
RS (1) RS20060344A (fr)
RU (1) RU2357731C2 (fr)
SG (1) SG149078A1 (fr)
TW (1) TWI286935B (fr)
WO (1) WO2005046689A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1574211A1 (fr) 2004-03-09 2005-09-14 Inserm Utilisation d'antagonistes des récepteurs CB1 pour la fabrication d'un médicament destiné au traitement des maladies hépatiques
WO2007009700A2 (fr) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Utilisation de composes pyrazoliniques substitues pour le traitement de parametres des lipides du syndrome metabolique
EP1745782A1 (fr) * 2005-07-15 2007-01-24 Laboratorios Del Dr. Esteve, S.A. Utilisation de pyrazolines substituées pour la fabrication d' un médicament pour le traitement de la syndrome métabolique
EP1745781A1 (fr) * 2005-07-15 2007-01-24 Laboratorios Del Dr. Esteve, S.A. Combinaison d'antagoniste du récepteur cannabinoide du type pyrazoline et de statin
WO2007009694A1 (fr) * 2005-07-15 2007-01-25 Laboratorios Del Dr.Esteve, S.A. Utilisation de composes pyrazoliniques substitues pour l'elaboration de medicaments destines au traitement du syndrome metabolique
ES2330993B1 (es) * 2005-07-15 2010-07-06 Laboratorios Del Dr. Esteve, S.A. Combinacion de antagonista del receptor de cannabinoides de tipo pirazolina y estatina.
EP1946779A1 (fr) * 2007-01-16 2008-07-23 Laboratorios del Dr. Esteve S.A. Combination de pyrazoline substitués et de médicaments contre la dyslipidémie
EP1985295A1 (fr) 2007-04-04 2008-10-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Inhibiteurs sélectifs de l'expression du récepteur CB2 et/ou activité pour le traitement de l'obésité et troubles liés à l'obésité
KR101057485B1 (ko) 2008-08-04 2011-08-17 서울대학교산학협력단 1,2-디티올티온 유도체를 함유하는 엘엑스알-알파 과다발현으로 인한 질병의 예방 및 치료용 약학 조성물
WO2010079241A1 (fr) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Utilisation d'antagonistes et/ou d'agonistes inverses des récepteurs cb1 pour la préparation de médicaments qui augmentent l'excitabilité des motoneurones
ES2349838B1 (es) * 2009-05-04 2011-11-15 Instituto Mediterraneo Para El Avance De La Biotecnologia Y La Investigacion Sanitaria (Fundacion Im Derivados de pirazol bivalentes como inhibidores de ingesta
RU2568896C2 (ru) * 2013-07-31 2015-11-20 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Лекарственное средство на основе вещества, влияющего на эндоканнабиноидную систему
CA3077624A1 (fr) * 2016-10-01 2018-04-05 James Smeeding Compositions pharmaceutiques comprenant une statine et un cannabinoide et leurs utilisations

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
FR2799124B1 (fr) * 1999-10-01 2004-08-13 Sanofi Synthelabo Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
FR2814678B1 (fr) * 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
US20020091114A1 (en) * 2000-10-04 2002-07-11 Odile Piot-Grosjean Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
MXPA04002583A (es) * 2001-09-21 2004-06-18 Solvay Pharm Bv Derivados de 4,5-dihidro-1h-pirazol novedosos que tienen actividad antagonistica del canabinoide (cb1).
US6864268B2 (en) * 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
NZ534757A (en) * 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
CA2480856A1 (fr) * 2002-04-05 2003-10-23 Merck & Co., Inc. Arylamides substituee
GEP20084475B (en) * 2002-07-09 2008-09-10 Bristol Myers Squibb Co Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method for their production
JP2005533849A (ja) * 2002-07-18 2005-11-10 メルク　エンド　カムパニー　インコーポレーテッド 肥満治療のための組み合わせ療法
ATE375349T1 (de) * 2002-08-02 2007-10-15 Merck & Co Inc Substituierte furo(2,3-b)pyridin derivate
AU2003296895A1 (en) * 2002-08-20 2004-05-04 The Regents Of The University Of California Combination therapy for controlling appetites
US6869966B2 (en) * 2002-09-30 2005-03-22 Banyu Pharmaceutical Co., Ltd. N-substituted-2-oxodihydropyridine derivatives
US20040214804A1 (en) * 2003-04-25 2004-10-28 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-obesity agent
US20060160834A1 (en) * 2003-06-06 2006-07-20 Fong Tung M Combination therapy for the treatment of hypertension
WO2004110375A2 (fr) * 2003-06-06 2004-12-23 Merck & Co., Inc. Polytherapie permettant de traiter le diabete
US20060148721A1 (en) * 2003-06-06 2006-07-06 Erondu Ngozi E Combination therapy for the treatment of dyslipidemia
EP1663215A1 (fr) * 2003-09-02 2006-06-07 Solvay Pharmaceuticals GmbH Nouvelle utilisation medicale d'antagonistes selectifs du receptor cb1
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
RU2006117637A (ru) * 2003-10-24 2007-12-10 Зольвай Фармасьютиклз Гмбх (De) Комбинированное лечение ожирения с применением избирательных антагонистов cb1-рецептора и ингибиторов липаз
EP1574211A1 (fr) * 2004-03-09 2005-09-14 Inserm Utilisation d'antagonistes des récepteurs CB1 pour la fabrication d'un médicament destiné au traitement des maladies hépatiques
JP2007533661A (ja) * 2004-03-31 2007-11-22 ニューロジェン・コーポレーション 体重管理のための併用療法
US20050281868A1 (en) * 2004-06-21 2005-12-22 Fairfield Clinical Trials, Llc Transdermal delivery system for statin combination therapy

Also Published As

Publication number Publication date
MA28105A1 (fr) 2006-08-01
KR20060100443A (ko) 2006-09-20
AR063551A2 (es) 2009-01-28
AU2004289078A1 (en) 2005-05-26
RU2357731C2 (ru) 2009-06-10
AR047764A1 (es) 2006-02-22
IL175103A0 (en) 2008-04-13
AR063550A2 (es) 2009-01-28
EP1680117A2 (fr) 2006-07-19
SG149078A1 (en) 2009-01-29
CA2543582A1 (fr) 2005-05-26
WO2005046689A3 (fr) 2005-10-13
BRPI0415538A (pt) 2006-12-26
US20090215755A1 (en) 2009-08-27
TW200526216A (en) 2005-08-16
US20070072907A1 (en) 2007-03-29
TWI286935B (en) 2007-09-21
WO2005046689A2 (fr) 2005-05-26
JP2007509113A (ja) 2007-04-12
RS20060344A (en) 2008-08-07
NZ547375A (en) 2009-10-30
RU2006117790A (ru) 2007-12-10
FR2861303A1 (fr) 2005-04-29

Similar Documents

Publication Publication Date Title
MEP10608A (en) Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity
ATE402697T1 (de) 1,3,5-trisubstituierte 4,5-dihydro-1h-pyrazol- derivative mit cb1-antagonistischer aktivität
EE04836B1 (et) N-piperidino-5-(4-klorofenüül)-1-(2,4-diklorofenüül)-4-metüülpürasool-3-karboksamii di kasutamine ravimtoodete valmistamiseks, aitamaks loobuda tubakatarbimisest
WO2005000820A3 (fr) Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application comme antagonistes des recepteurs aux cannabinoides cb1
NO20064603L (no) Anvendelse av antagonister av CBI-reseptoren av preparat anvendelig for behandling av leversykdommer.
CO5160257A1 (es) La n-piperidino-5-(4-bromofenil)-1-(2,4-diclorofenil)-4-etilpirazol-3-carboxamida, sus sales, su preparacion y las composiciones farmaceuticas que la contienen
RS49606B (sr) Farmaceutski preparat derivata n- piperidino-3- pirazolkarboksamida, njegovih soli i njihovih solvata za oralnu administraciju
FR2849032B1 (fr) Derive de 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-n -(piperidin-1-yl)-1h-pyrazole-3-carboxamide, sa preparation, son application en therapeuthique
TW200716135A (en) Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
WO2007123949A3 (fr) Modulateurs des recepteurs des cannabinoides
WO2007017126A3 (fr) Polymorphe d'une pyrazoline substituee, sa preparation et son utilisation comme medicaments
IL191936A0 (en) 4,5-dihydro-(1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators
HRP20090393T1 (en) Pharmaceutical composition for oral administration of a pyrazol-3-carboxamide derivative
NO20062369L (no) Anvendelse av et pyrazoldedvat for fiemstilling av medikamenter for a hindre og behandle dyslipideml og sykdommer assosiert med dyslipidemi og/eller fedme
ATE500228T1 (de) 4,5-dihydro-(1h)-pyrazol-derivate als cannabinoid-cb1-rezeptormodulatoren
AR049475A1 (es) Utilizacion de un derivado de pirazol para la preparacion de medicamentos utiles en la prevencion y el tratamiento de la bronquitis cronica, y de la bronconeumopatia cronica obstructiva
ES2328328A1 (es) Polimorfo alfa de una pirazolina sustituida, su preparacion y su uso como medicamento
ES2331278A1 (es) Polimorfo gamma de una pirazolina sustituida, su preparacion y su uso como medicamento.
ES2328327A1 (es) Fase amorfa de una pirazolina sustituida, su preparacion y su uso comomedicamento.
TH81014B (th) การใช้อนุพันธ์ไพราโซลสำหรับการเตรียมผลิตภัณฑ์ยาซึ่งใช้ในการป้องกัน และการรักษาโรคไต
TH74718A (th) การใช้อนุพันธ์ของไพราโซลสำหรับการเตรียมผลิตภัณฑ์ทางยาซึ่งใช้ได้ดีในการป้องกันและการบำบัดหลอมลมอักเสบแบบเรื้อรังและโรคปอดอุดตันแบบเรื้อรัง
EA201070019A1 (ru) 4,5-дигидро-(1н)-пиразольные производные как модуляторы каннабиноидных св-рецепторов
TH81014A (th) การใช้อนุพันธ์ไพราโซลสำหรับการเตรียมผลิตภัณฑ์ยาซึ่งใช้ในการป้องกัน และการรักษาโรคไต
UA84594C2 (en) 1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives as cb1 antagonists
DOP2004001017A (es) Utilizacion de un derivado de pirazol para la preparacion y el tratamiento de las dislipidemias y de las enfermedades asociadas a las dislipidemias y/o a la obesidad